While broader UK indices face headwinds, a closer look reveals potential in smaller-cap companies. We examine three penny stocks—Alumasc Group, Mercia Asset Management, and Roebuck Food Group—that are navigating economic challenges with distinct strategies and financial profiles.
A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.
The spirits giant files for legal protection for its production and warehouse assets in Latvia, citing cash flow pressures from geopolitical fallout and market headwinds, while assuring global sales remain unaffected.
A woman claiming to be a former girlfriend of TRON founder Justin Sun has made a series of unverified yet damaging public allegations, reviving scrutiny of his ongoing SEC case and accusing him of orchestrating wash trading. The claims also unexpectedly link Sun to Olympic skier Eileen Gu.
In a striking departure from her once-fervent loyalty, former Congresswoman Marjorie Taylor Greene has launched a scathing critique of Donald Trump and his MAGA movement, accusing him of abandoning his base for wealthy donors and foreign interests, particularly Israel.
Amidst shifting economic currents in Asia, a class of smaller companies—often overlooked as 'penny stocks'—is attracting attention for their distinct financial profiles and niche market positions. We analyze three such firms with market capitalizations below US$200 million.
Analyses from multiple artificial intelligence models project divergent paths for Ethereum, Solana, and XRP by 2026, highlighting varying risk-reward profiles based on technological adoption, regulatory landscapes, and market structure.
As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.
In its latest investor letter, David Einhorn's Greenlight Capital revealed it has sold its stake in HP Inc., redirecting capital towards AI-focused investments it believes offer superior risk-reward profiles amid the tech giant's recent struggles.
As volatility returns to European markets, investors are turning to dividend-paying stocks for income and stability. We examine three companies with compelling, yet distinct, dividend profiles for income-focused portfolios.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, citing insufficient evidence. The complaint stemmed from the judge's rulings against the Trump administration's use of the Alien Enemies Act to deport Venezuelan migrants.
A federal appeals court has dismissed a Justice Department misconduct complaint against U.S. District Judge James Boasberg, ruling the government failed to substantiate its allegations regarding the judge's public comments.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
First Pacific Advisors' FPA Crescent Fund disclosed it sold its position in tech giant Microsoft in Q4 2025. The value-focused fund explained the move was driven by a search for greater upside in other AI-related investments, despite acknowledging Microsoft's strong fundamentals.
Giverny Capital's latest investor letter highlights Arista Networks as a standout performer, driven by strong earnings and strategic positioning in the high-speed networking sector crucial for AI and cloud expansion.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.
While small-cap stocks offer significant growth potential, their volatility demands careful selection. We analyze one standout and two struggling companies in the Russell 2000 index this week.
